DE602004017783D1 - Pharmazeutische sprayformulierung mit einem hydrofluoralkan und einem acylierten cyclodextrin - Google Patents

Pharmazeutische sprayformulierung mit einem hydrofluoralkan und einem acylierten cyclodextrin

Info

Publication number
DE602004017783D1
DE602004017783D1 DE602004017783T DE602004017783T DE602004017783D1 DE 602004017783 D1 DE602004017783 D1 DE 602004017783D1 DE 602004017783 T DE602004017783 T DE 602004017783T DE 602004017783 T DE602004017783 T DE 602004017783T DE 602004017783 D1 DE602004017783 D1 DE 602004017783D1
Authority
DE
Germany
Prior art keywords
hydrofluoroal
spray formulation
pharmaceutical spray
acylated cyclodextrin
acylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE602004017783T
Other languages
German (de)
English (en)
Inventor
Philippe Rogueda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of DE602004017783D1 publication Critical patent/DE602004017783D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
DE602004017783T 2003-11-26 2004-11-24 Pharmazeutische sprayformulierung mit einem hydrofluoralkan und einem acylierten cyclodextrin Expired - Lifetime DE602004017783D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0303179A SE0303179D0 (sv) 2003-11-26 2003-11-26 Novel compounds
PCT/GB2004/004957 WO2005053637A2 (en) 2003-11-26 2004-11-24 Pharmaceutical spray formulation comprising a hypro fluor alkane amd an acylated cyclodextrin

Publications (1)

Publication Number Publication Date
DE602004017783D1 true DE602004017783D1 (de) 2008-12-24

Family

ID=29729189

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004017783T Expired - Lifetime DE602004017783D1 (de) 2003-11-26 2004-11-24 Pharmazeutische sprayformulierung mit einem hydrofluoralkan und einem acylierten cyclodextrin

Country Status (23)

Country Link
US (1) US20070104652A1 (enExample)
EP (1) EP1708679B1 (enExample)
JP (1) JP4950666B2 (enExample)
KR (1) KR20060118509A (enExample)
CN (1) CN100592908C (enExample)
AT (1) ATE413868T1 (enExample)
AU (1) AU2004294775B2 (enExample)
BR (1) BRPI0416992A (enExample)
CA (1) CA2546441C (enExample)
CY (1) CY1108753T1 (enExample)
DE (1) DE602004017783D1 (enExample)
DK (1) DK1708679T3 (enExample)
ES (1) ES2314469T3 (enExample)
IL (1) IL175659A (enExample)
MX (1) MXPA06005643A (enExample)
NO (1) NO20062969L (enExample)
NZ (1) NZ547355A (enExample)
PL (1) PL1708679T3 (enExample)
PT (1) PT1708679E (enExample)
SE (1) SE0303179D0 (enExample)
SI (1) SI1708679T1 (enExample)
WO (1) WO2005053637A2 (enExample)
ZA (1) ZA200604330B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006008568A (ja) * 2004-06-24 2006-01-12 Cyclochem:Kk IgE抗体抑制剤および食品
JPWO2023127219A1 (enExample) * 2021-12-28 2023-07-06

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
US5654442A (en) * 1989-11-14 1997-08-05 The Perkin-Elmer Corporation 4,7-dichlorofluorescein dyes as molecular probes
TW249226B (enExample) * 1990-04-04 1995-06-11 Aderk Ueno Kk
EP0477931B1 (en) * 1990-09-28 1994-08-17 Mercian Corporation Novel adriamycin derivatives
FR2692168B1 (fr) * 1992-06-16 1995-03-24 Centre Nat Rech Scient Préparation et utilisation de nouveaux systèmes colloïdaux dispersibles à base de cyclodextrine, sous forme de nanosphères.
US5916883A (en) * 1996-11-01 1999-06-29 Poly-Med, Inc. Acylated cyclodextrin derivatives
GB2326334A (en) * 1997-06-13 1998-12-23 Chiesi Farma Spa Pharmaceutical aerosol compositions
GB9807232D0 (en) * 1998-04-03 1998-06-03 Univ Cardiff Aerosol composition
IT1303788B1 (it) * 1998-11-25 2001-02-23 Chiesi Farma Spa Formulazioni di aerosol medicinali.
DE10205087A1 (de) * 2002-02-07 2003-08-21 Pharmatech Gmbh Cyclodextrine als Suspensionsstabilisatoren in druckverflüssigten Treibmitteln

Also Published As

Publication number Publication date
AU2004294775B2 (en) 2007-12-20
ZA200604330B (en) 2007-11-28
HK1108390A1 (zh) 2008-05-09
US20070104652A1 (en) 2007-05-10
JP2007515401A (ja) 2007-06-14
PT1708679E (pt) 2008-12-29
NO20062969L (no) 2006-08-25
CY1108753T1 (el) 2014-04-09
JP4950666B2 (ja) 2012-06-13
SE0303179D0 (sv) 2003-11-26
WO2005053637A3 (en) 2007-06-28
CN101087600A (zh) 2007-12-12
CA2546441C (en) 2011-11-22
IL175659A (en) 2010-02-17
CA2546441A1 (en) 2005-06-16
KR20060118509A (ko) 2006-11-23
ES2314469T3 (es) 2009-03-16
ATE413868T1 (de) 2008-11-15
WO2005053637A2 (en) 2005-06-16
EP1708679B1 (en) 2008-11-12
CN100592908C (zh) 2010-03-03
IL175659A0 (en) 2006-09-05
SI1708679T1 (sl) 2009-04-30
BRPI0416992A (pt) 2007-02-06
PL1708679T3 (pl) 2009-04-30
NZ547355A (en) 2009-05-31
EP1708679A2 (en) 2006-10-11
AU2004294775A1 (en) 2005-06-16
MXPA06005643A (es) 2006-08-17
DK1708679T3 (da) 2009-02-16

Similar Documents

Publication Publication Date Title
ATE496064T1 (de) Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
IL184051A (en) Acetylated GLP-1 compounds, containing and using pharmaceutical preparations
IL231576A (en) Derivatives of adamantyl-acetamide, the pharmaceutical compositions containing them and their use in the preparation of medicines
BR0210519A (pt) Composições farmacêuticas de adsorvatos de fármaco amorfo
WO2006128121A3 (en) Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
UA88464C2 (ru) Способ дермального введения метадоновой композиции с обеспечением системного действия
HRP20060240T3 (hr) Intranazalni pripravak rotigotina
UY28175A1 (es) Formulaciones farmaceuticas liquidas de palonosetron
ITFI20050042A1 (it) N-idrossiammidi -sostituiti con gruppi triciclici come inibitori dell'istone deacelitasi,loro preparazione ed impiego in formulazioni farmaceutiche
WO2001066601A8 (en) Clathrate complexes formed by hyaluronic acid derivatives and use thereof as pharmaceuticals
SI1909843T1 (sl) Protitumorski biokonjugati hialuronske kisline ali njenih derivatov, dobljeni z indirektno kemijsko konjugacijo, in njihova uporaba na farmacevtskem področju
CY1110664T1 (el) Ενδορινικες συνθεσετς
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
DK1543063T3 (da) Medikament levering
PA8579801A1 (es) Composiciones farmaceuticas de farmacos semiordenados y polimeros
WO2023001248A9 (zh) 一种含抗trop2抗体药物偶联物的药物组合物及其用途
WO2006089993A3 (es) Procedimiento de obtención de hidrogeles de ciclodextrinas con glicidiléteres, las composiciones obtenidas y sus aplicaciones
DE60221227D1 (de) Xanthangummi enthaltende reepithelialisierende pharmazeutische Zubereitungen
DE60142913D1 (de) Arzneilösungen enthaltend modafinilverbindungen
WO2007060512A3 (en) Compositions containing topical active agents and pentylene glycol
DE602004017783D1 (de) Pharmazeutische sprayformulierung mit einem hydrofluoralkan und einem acylierten cyclodextrin
NO20076120L (no) Stabile nanopartikkelformuleringer
ITBO20020544A1 (it) Uso di farine vegetali come agenti biotossici ad azione ammendante.
ATE402706T1 (de) Im mund zerfallende pharmazeutische zusammensetzung mit risperidon
NL1022442C2 (nl) Toepassing van lipide ter verbetring van de opname van nutrienten en (farmaceutisch) actieve stoffen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition